Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma

Adam L. Burrack, Ellen J. Spartz, Jackson F. Raynor, Iris Wang, Margaret Olson, Ingunn M. Stromnes

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Burrack et al. investigate tumor-specific T cells during immunotherapy of pancreas cancer. T cells accumulate intratumorally yet rapidly exhaust. Combined PD-1 + PD-L1 blockade promotes peripheral T cell expansion, TNFα production, and eradication of spontaneous tumor recurrence in 50% of animals. Tumor variants defective in IFNγ-inducible Tap1 and MHC class I ultimately emerge.

Original languageEnglish (US)
Pages (from-to)2140-2155.e6
JournalCell reports
Volume28
Issue number8
DOIs
StatePublished - Aug 20 2019

Keywords

  • PD-1
  • PD-L1
  • PDA
  • T cells
  • acquired resistance
  • immunotherapy
  • neoepitope
  • pancreatic cancer

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma'. Together they form a unique fingerprint.

Cite this